Failure mode and effects analysis drastically reduced potential risks in clinical trial conduct

被引:15
作者
Lee, Howard [1 ,2 ]
Lee, Heechan [1 ,2 ]
Baik, Jungmi [3 ]
Kim, Hyunjung [3 ]
Kim, Rachel [4 ]
机构
[1] Seoul Natl Univ, Coll Med & Hosp, Dept Clin Pharmacol & Therapeut, 101 Daehak Ro, Seoul 03080, South Korea
[2] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Transdisciplinary Studies, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Clin Trials Ctr, Seoul, South Korea
[4] Pfizer Korea, Global Clin Trial Execut, Seoul, South Korea
来源
DRUG DESIGN DEVELOPMENT AND THERAPY | 2017年 / 11卷
关键词
clinical trial; failure modes and effects analysis; quality improvement; quality management; quality risks; DOSE-RATE BRACHYTHERAPY; ANALYSIS FMEA; IMPLEMENTATION; INTERVENTION; MORTALITY; UNIT;
D O I
10.2147/DDDT.S145310
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Failure mode and effects analysis (FMEA) is a risk management tool to proactively identify and assess the causes and effects of potential failures in a system, thereby preventing them from happening. The objective of this study was to evaluate effectiveness of FMEA applied to an academic clinical trial center in a tertiary care setting. Methods: A multidisciplinary FMEA focus group at the Seoul National University Hospital Clinical Trials Center selected 6 core clinical trial processes, for which potential failure modes were identified and their risk priority number (RPN) was assessed. Remedial action plans for high-risk failure modes (RPN. 160) were devised and a follow-up RPN scoring was conducted a year later. Results: A total of 114 failure modes were identified with an RPN score ranging 3-378, which was mainly driven by the severity score. Fourteen failure modes were of high risk, 11 of which were addressed by remedial actions. Rescoring showed a dramatic improvement attributed to reduction in the occurrence and detection scores by. 3 and. 2 points, respectively. Conclusions: FMEA is a powerful tool to improve quality in clinical trials. The Seoul National University Hospital Clinical Trials Center is expanding its FMEA capability to other core clinical trial processes.
引用
收藏
页码:3035 / 3043
页数:9
相关论文
共 22 条
  • [1] [Anonymous], 2006, Guidance for industry. Q9 quality risk management
  • [2] Asefzadeh S, 2013, INT J PREVENTIVE MED, V4, P592
  • [3] Ashley Laura, 2010, J Patient Saf, V6, P210, DOI 10.1097/PTS.0b013e3181fc98d7
  • [4] Bhatt Arun, 2011, Perspect Clin Res, V2, P124, DOI 10.4103/2229-3485.86880
  • [5] Bonfant G, 2010, J NEPHROL, V23, P111
  • [6] FMEA: A model for reducing medical errors
    Chiozza, Maria Laura
    Ponzetti, Clemente
    [J]. CLINICA CHIMICA ACTA, 2009, 404 (01) : 75 - 78
  • [7] Anticipating risk for human subjects participating in clinical research: Application of failure mode and effects analysis
    Cody, RJ
    [J]. CANCER INVESTIGATION, 2006, 24 (02) : 209 - 214
  • [8] DeRosier Joseph, 2002, Jt Comm J Qual Improv, V28, P248
  • [9] EMA, 2013, REFL PAP RISK BAS QU
  • [10] Use of failure mode, effect and criticality analysis to improve safety in the medication administration process
    Guadalupe Rodriguez-Gonzalez, Carmen
    Luisa Martin-Barbero, Maria
    Herranz-Alonso, Ana
    Isabel Durango-Limarquez, Maria
    Hernandez-Sampelayo, Paloma
    Sanjurjo-Saez, Maria
    [J]. JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2015, 21 (04) : 549 - 559